<DOC>
	<DOCNO>NCT01320696</DOCNO>
	<brief_summary>The purpose study identify optimal dose level reverse genetic ( RG ) reassortant H9N2 pandemic influenza vaccine product development .</brief_summary>
	<brief_title>Reverse Genetic H9N2 Influenza Vaccine Study Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 18 49 year age , inclusive , day screen Subject understand study procedure , agree provision , give write informed consent prior study entry Subject generally healthy , determine investigator 's clinical judgement collection medical history performance physical examination Subject physically mentally capable participate study determine investigator Subject agree keep daily record symptom duration study If female childbearing potential , subject present negative urine pregnancy test within 24 hour prior first vaccination agree employ adequate birth control measure duration study . For purpose study least one follow type US Food Drug Administration ( FDA ) approve birth control measure shall apply completion Day 181 study visit : Hormonal type birth control ( implant birth control pill ) intrauterine device A barrier type birth control measure ( i.e . condom , diaphragm , cervical cap , etc . ) Subject history exposure H9N2 influenza virus history vaccination H9N2 influenza vaccine Subject potential occupational risk contract H9N2 influenza infection ( e.g . poultry worker ) Subject currently suffer history significant ( require hospitalization change intervention past 6 month ) neurological , cardiovascular , pulmonary ( include asthma ) , hepatic , rheumatic , autoimmune , hematological , metabolic renal disorder limit : multiple sclerosis , lupus , GuillainBarre syndrome determine investigator Subject body temperature &gt; = 100.4 degree Fahrenheit ( &gt; = 38.0 degree Celsius ) day vaccination , oral measurement . [ NOTE : Subjects meet exclusion criterion may reschedule vaccination study entry later date provide : 1 ) body temperature measure orally decrease &lt; 100.4 degree Fahrenheit ( &lt; 38.0 degree Celsius ) ; 2 ) inclusion/exclusion criterion meet ; 3 ) reschedule date 14 day past initial screening assessment date ; 4 ) study site still enrol subject randomization close ] Subject Body Mass Index ( BMI ) &gt; = 35 Subject hypertension screening grade great Stage 1 ( define systolic pressure &gt; 159 diastolic pressure &gt; 99 seat rest ( measurement shall repeat twice subject exclude ) Subject clinically significant abnormal laboratory value screen determine investigator Subject test positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface Antigen ( HBsAgs ) Hepatitis C Virus ( HCV ) Subject medically diagnose suspect immune deficient condition base medical history physical examination determine investigator Subject immune compromise condition disease , currently undergo form treatment undergoing form treatment within 30 day prior study entry expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800 Î¼g/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug ( use inhale nasal steroid permit ) Subject history severe ( required immediate medical life threaten treatment and/or hospitalization ) allergic reaction anaphylaxis determine investigator Subject rash , dermatologic condition tattoo may interfere injection site reaction rating determine investigator Subject receive blood product ( e.g . blood transfusion immunoglobulin ) within 90 day prior study entry Subject donate one unit blood ( approximately 450 mL ) plasma within 30 day prior study entry Subject receive live vaccine within 4 week inactivate vaccine subunit vaccine within 2 week prior vaccination study Subject functional surgical asplenia Subject positive urine drug screen ( unless subject currently prescribe drug detect license health care provider continue administration drug would otherwise exclude subject participation ) Subject know suspect problem alcohol drug abuse determine investigator Subject currently enrol participate another clinical study involve investigational product ( IP ) device within 30 day prior study enrollment schedule participate another clinical study involve IP device course study Subject member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( i.e . child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct study If female , subject pregnant lactating time study enrollment Any condition opinion investigator would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>